CAMBRIDGE, Mass., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in
precision genetic medicine for rare diseases, announced that commencing at 8:00 a.m. Eastern Time (ET) on Wednesday February 27,
2019, it will host a webcast and conference call to announce results from the first 3-patient cohort of the phase I/IIa gene
transfer clinical trial using MYO-101 to treat patients with Limb-Girdle Muscular Dystrophy Type 2E (beta-sarcoglycanopathy).
Sarepta also announced that it will report fourth quarter and full-year 2018 financial results after the Nasdaq
Global Market closes on Wednesday, February 27, 2019. Subsequently, at 4:30 p.m. ET on February 27, 2019, the Company will host a
conference call to discuss its fourth quarter and full-year 2018 financial results and to provide a corporate update.
The 8:00 a.m. ET conference call presenting the MYO-101 LGMD results may be accessed by dialing (844) 534-7313
for domestic callers and (574) 990-1451 for international callers. The passcode for the call is 1693875. Please specify to the
operator that you would like to join the “Sarepta hosted LGMD results Call.”
The 4:30 p.m. ET conference call to discuss fourth quarter and full-year 2018 results and corporate updates may
be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. The passcode for the call
is 3768408. Please specify to the operator that you would like to join the “Sarepta Fourth Quarter and Full-Year 2018 Earnings
Call."
Both conference calls will be webcast live under the investor relations section of Sarepta's website at
www.sarepta.com and will be archived there following the call for 90 days. Please connect to
Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be
necessary.
About Sarepta Therapeutics
Sarepta is at the forefront of precision genetic medicine, having built an impressive and competitive position in Duchenne muscular
dystrophy (DMD) and more recently in gene therapies for 5 Limb-girdle muscular dystrophy diseases (LGMD), Charcot-Marie-Tooth
(CMT), MPS IIIA, Pompe and other CNS-related disorders, totaling over 20 therapies in various stages of development. The Company’s
programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. Sarepta is fueled by
an audacious but important mission: to profoundly improve and extend the lives of patients with rare genetic-based diseases. For
more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our
website at www.sarepta.com. We encourage investors and potential investors to
consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc.
Investors:
Ian Estepan, 617-274-4052
iestepan@sarepta.com
Media:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com
